Fibrinolytic therapy in pulmonary embolism: an evidence-based treatment algorithm

American Journal of Emergency Medicine

Volumn 27, Issue 1, 2009, Pages 84-95

  Fengler, Brian T ^a   Brady, William J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

ALGORITHM; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; DISEASE SEVERITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HEART ARREST; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYNCOPE; THROMBECTOMY;

ALGORITHMS; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; PULMONARY EMBOLISM; THROMBOLYTIC THERAPY;

EID: 56549112592     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2007.10.021     Document Type: Review

References (73)

1. Kasper W., Konstantinides S., et al. Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism; results of a multicenter registry (MAPPET). J Am Coll Cardiol 30 (1997) 1165-1171
2. Wan S., Quinlan D.J., et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 110 (2004) 744-749
3. Buller H.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 3 (2004) 401s-420s
4. Pollack, Diercks D.B., et al. 2004 American College of Cardiology/American Heart Association guidelines for the management of patients with ST-elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 45 (2005) 363-376
5. Albers G.W., Amarenco P., et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 483S-512S
6. Tibbutt D.A., Davies J.A., Anderson J.A., et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J 1 (1974) 343-347
7. Levine M., Hirsh J., et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 98 (1990) 1473-1479
8. Dalla-Volta S., Palla A., et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 20 (1992) 520-526
9. Sharma G.V., Folland E.D., et al. Long-term hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease. JACC (1990) 65A [abstract only]
10. Ribeiro A., Lindmarker P., et al. Pulmonary embolism; one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 99 (1999) 1325-1330
11. Cannon C.P., and Goldhaber S.Z. Cardiovascular risk stratification of pulmonary embolism. Am J Cardio 78 (1996) 1149-1151
12. Goldhaber S.Z. Pulmonary embolism thrombolysis: broadening the paradigm for its administration. Circulation 96 (1997) 716-718
13. Loebinger M.R., and Bradley J.C. Thrombolysis in pulmonary embolism: are we under-using it?. Q J Med 97 (2004) 361-364
14. Goldhaber S.Z. Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction, pro. Arch Intern Med 165 (2005) 2197-2199
15. Dalen J.E. The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism. Arch Intern Med 162 (2002) 2521-2523
16. Thabut G., and Logeart D. Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction, con. Arch Intern Med 165 (2005) 2200-2203
17. Perlroth D.J., Sanders G.D., et al. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med 167 (2007) 74-80
18. Worster A., Smith C., et al. Thrombolytic therapy for sumbmassive pulmonary embolism?. Ann Emerg Med 50 (2007) 78-84
19. Goldhaber S.Z., Visani L., et al. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353 (1999) 1386-1389
20. Newman D.H., Greenwalk I., and Callaway C.W. Cardiac arrest and the role of thrombolytic agents. Ann Emerg Med 35 (2000) 472-480
21. Bottiger B.W., Bode C., et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 357 (2001) 1583-1585
22. Lederer W., Lichtenberger C., et al. Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. Resuscitation 50 (2001) 71-76
23. Ruiz-Bailen M., and Aguayo de Hoyos E. Efficacy of thrombolysis in patients with acute myocardial infarction requiring cardiopulmonary resuscitation. Intensive Care Med 27 (2001) 1050-1057
24. Voipio V., Kuisma M., et al. Thrombolytic treatment of acute myocardial infarction after out-of-hospital cardiac arrest. Resuscitation 49 (2001) 251-258
25. Bozeman W.P., Kleiner D.M., and Ferguson K.L. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. Resuscitation 69 (2006) 399-406
26. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 58 (2003) 470-484
27. Janata K., Holzer M., et al. Major bleeding complications in cardiopulmonary resuscitation: the place of thrombolytic therapy in cardiac arrest due to massive pulmonary embolism. Resuscitation 57 (2003) 49-55
28. Scholz K.H., Tebbe U., et al. Frequency of complications of cardiopulmonary resuscitation after thrombolysis during acute myocardial infarction. Am J Cardiol 69 (1992) 724-728
29. Stulz P., Schlapfer R., et al. Decision making in the surgical treatment of massive pulmonary embolism. Eur J Cardiothorac Surg 8 (1994) 188-193
30. Le Conte P., Huchet L., et al. Efficacy of alteplase thrombolysis for ED treatment of pulmonary embolism with shock. Am J Emerg Med 21 (2003) 438-440
31. Koroneos A., Koutsoukou A., et al. Successful resuscitation with thrombolysis of a patient suffering fulminant pulmonary embolism after recent intracerebral hemorrhage. Resuscitation 72 (2007) 154-157
32. Han S., Chaya C., and Soo Hoo G. Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor. J Intensive Care Med 21 (2006) 240-245
33. Stefanovic B.S., Vasiljevic Z., et al. Thrombolytic therapy for massive pulmonary embolism 12 hours after cesarean delivery despite contraindication?. Am J Emerg Med 4 (2006) 502-504
34. Jerjes-Sanchez C., Ramirez-Rivera A., et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism; a randomized controlled trial. J Thromb Thrombolysis 2 (1995) 227-229
35. Grifoni S., Olivotto I., et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 101 (2000) 2817-2822
36. Konstantinides S., Geibel A., et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 106 (2002) 1263-1268
37. Konstantinides S., and Geibel A. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism. Circulation 96 (1997) 882-888
38. Kreit J.W. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 125 (2004) 1539-1545
39. Goldhaber S.Z. Echocardiography in the management of pulmonary embolism. Ann Intern Med 136 (2002) 691-700
40. Konstantinides S., Geibel A., et al. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 97 (1998) 1946-1951
41. Kronik G. The European working group on echocardiography. The European cooperative study on the clinical significance of right heart thrombi. Eur Heart J 10 (1989) 1046-1059
42. Chartier L., and Bera J. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation 99 (1999) 2779-2783
43. Rose P.S., Punjabi N.M., and Pearse D.B. Treatment of right heart thromboemboli. Chest 121 (2002) 806-814
44. ten Wolde M., Tulevski I.I., et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 107 (2003) 2082-2084
45. Kucher N., Printzen G., and Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 107 (2003) 2545-2547
46. Kucher N., Wallman D., et al. Incremental prognostic value of troponin I and echocardiography in patients with acute pulmonary embolism. Euro Heart J 24 (2003) 1651-1656
47. Binder L., Pieske B., et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 112 (2005) 1573-1579
48. Thames M.D., Alpert J.S., and Dalen J.E. Syncope in patients with pulmonary embolism. JAMA 238 (1977) 2509-2511
49. Goldhaber S.Z., Haire W.D., et al. Alteplase versus heparin in acute pulmonary embolism; randomized trial assessing right ventricular function and pulmonary perfusion. Lancet 341 (1993) 507-511
50. Konstantinides S., Geibel A., et al. Management Strategies and Prognosis of Pulmonary Embolism-3 trial investigators (MAPPET-3). Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347 (2002) 1143-1150
51. Agnelli G., Becattini C., et al. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 162 (2002) 2537-2541
52. Kanter D.S., and Mikkola K.M. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest 111 (1997) 1241-1245
53. Meneveau N., Ming L.P., et al. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J 24 (2003) 1447-1454
54. Chaitman B.R., Thompson B., et al. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: Results from Thrombolysis in Myocardial Infarction phase I, open label studies and the Thrombolysis in Myocardial Infarction phase II pilot study. J Am Coll Cardiol 14 (1989) 1159-1165
55. Simoons M.L., Maggioni A.P., et al. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 342 (1993) 1523-1528
56. Mikkola K.M., and Patel S.R. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 134 (1997) 69-72
57. Goldhaber S.Z., Agnelli G., and Levine M.N. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis: an international multi-center randomized trial. Chest 106 (1994) 718-724
58. Sors H., Pacouret G., et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest 106 (1994) 712-717
59. Tebbe U., Graf A., et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 138 1 (1999) 39-44
60. Theron C., and Laidlow D.C. Life threatening massive pulmonary embolism treated with reteplase: a case report. Crit Care Resuscitation 2 (2000) 278-281
61. Melzer C., Richter C., et al. Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thromb 18 1 (2004) 47-50
62. Kline J., Hernandez-Nino J., and Jones A.E. Tenecteplase to treat pulmonary embolism in the emergency department. J Thromb Thrombolysis 23 (2007) 101-105
63. Assessment of the safety and efficacy of a new thrombolytic investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet 354 (1999) 716-722
64. Goldhaber S.Z. Rebuttal. Arch Int Med 165 (2005) 2204
65. Kucher N., and Goldhaber S.Z. Management of massive pulmonary embolism. Circulation 112 (2005) e28-e32
66. Cross F.S., and Mowlem A. A survey of the current status of pulmonary embolectomy for massive pulmonary embolism. Circulation 35 (1967) 186-191
67. Aklog L., Williams C.S., et al. Acute pulmonary embolectomy: a contemporary approach. Circulation 105 (2002) 1416-1419
68. Yalamanchili K., Fleisher A.G., et al. Open pulmonary embolectomy for treatment of major pulmonary embolism. Ann Thorac Surg 77 (2004) 819-823
69. Leacche M., Unic D., et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 129 (2005) 1018-1023
70. Dauphine C., and Omari B. Pulmonary embolectomy for acute massive pulmonary embolism. Ann Thorac Surg 79 (2005) 1240-1244
71. Meneveau N., Seronde M.F., et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 129 (2006) 1043-1050
72. Kucher N., and Rossi E. Massive pulmonary embolism. Circulation 113 (2006) 577-582
73. Decousus H., Leizorovicz A., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 338 (1998) 409-415